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ABSTRACT
Introduction: The aim of this study was to
determine the level of awareness of hypo-
glycemia, the level of fear for hypoglycemia,
and the response to hypoglycemic events
among insulin-treated diabetes patients from
Central and Eastern Europe (CEE). The impact
of hypoglycemia on the use of healthcare
resources and patient productivity was also
assessed.
Methods: This was a multicenter, non-inter-
ventional, two-part, patient self-reported ques-
tionnaire study that comprised both a
retrospective cross-sectional evaluation and a
prospective observational evaluation. Study
participants were insulin-treated adult patients
with type 1 diabetes mellitus (T1DM) or type 2
diabetes mellitus (T2DM) from CEE.
Results: Most patients (85.4% T1DM and
83.6% T2DM) reported normal hypoglycemia
awareness. The median hypoglycemia fear score
was 5 out of 10 for T1DM and 4 out of 10 for
T2DM patients. Patients increased glucose
monitoring, consulted a doctor/nurse, and/or
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reduced the insulin dose in response to hypo-
glycemia. As a consequence of hypoglycemia,
patients took leave from work/studies or arrived
late and/or left early. Hospitalization was
required for 31 (1.2%) patients with T1DM and
66 (2.1%) patients with T2DM.
Conclusion: Hypoglycemia impacts patients’
personal and social functioning, reduces pro-
ductivity, and results in additional costs, both
direct (related to increased use of healthcare
resources) and indirect (related to absenteeism.
Funding: Novo Nordisk.
Keywords: Diabetes; Healthcare costs;
Hypoglycemia; Hypoglycemia fear; Insulin
therapy
INTRODUCTION
One of the most substantial risks related to the
treatment of diabetes mellitus (DM) is hypo-
glycemia, which negatively affects patient’s
health and overall quality of life (QoL) [1]. The
results of the ACCORD clinical trial showed that
intensive glucose-lowering therapy (with a tar-
get level of glycated hemoglobin [HbA1c] of\
6.0%) was associated with more frequent
hypoglycemic events requiring medical or non-
medical assistance and with higher mortality
than less intensive treatment regimens [2].
Among the many negative long-term conse-
quences of hypoglycemia, the higher risk of
micro- and macrovascular events with potential
fatal outcome is an important clinical concern
as such events may occur months or years after
episodes of severe hypoglycemia [3]. For exam-
ple, hypoglycemia has been shown to cause
cardiovascular (CV) events by increasing
inflammation, endothelial dysfunction, and
abnormal sympathoadrenal responses and by
activating blood coagulation [4]. Novel drugs
associated with lower risk of hypoglycemia (ei-
ther in monotherapy or as an addition to stan-
dard antidiabetic therapy) can, however, reduce
the CV risk in T2DM patients [5, 6]. Hypo-
glycemia can also affect cognitive function. For
example, a history of severe hypoglycemic
events has been associated with dementia [7].
Recurrent hypoglycemia has also been shown to
cause chronic mood disorders, including
depression and anxiety [8]. In addition, hypo-
glycemia has been shown to impair personal
and social functioning and reduce QoL in
patients with type 1 diabetes (T1DM) and type 2
diabetes (T2DM), resulting in problems related
to employment, the ability to drive a motor
vehicle, physical activity, and the fear of being
dependent on other family members or care-
givers. Indeed, this fear of dependency on
caregivers and loss of self-control has been
shown to influence the interpersonal relation-
ships of patients affected by hypoglycemia [9].
The American Diabetes Association (ADA)
clinical recommendations, published in 2017,
underline the essential role of patients in pre-
venting and managing hypoglycemia [1]. A
patient-centered approach not only includes
close direct communication, but also patient-
reported outcomes, structured and individual
patient education, individualized treatment,
and self-monitoring and self-management of
the DM [10]. Indeed, patients’ understanding of
the disease and its complications is a key factor
to the successful management of any chronic
disease, and DM with its risk of hypoglycemia is
no exception.
Nonetheless, the striking results of an anal-
ysis based on online questionnaires revealed
that 65% of patients with T1DM and 50–59% of
patients with T2DM rarely or never informed
their general practitioner/specialist of hypo-
glycemic events, while 16 and 26%, respec-
tively, had not been asked about hypoglycemia
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during routine visits [11]. Some patients did not
discuss hypoglycemia with their physicians
thinking that it is a ‘‘private issue’’ or a ‘‘personal
failure’’; others did not understand the impor-
tance of hypoglycemia [12].
Recently published findings of the HAT
study, a large global patient-reported study on
hypoglycemia, indicated high rates of hypo-
glycemia, with large variations between geo-
graphical regions [13]. These observed regional
differences in hypoglycemia incidence raised
the question as to whether they had resulted
from true ethnic and population variations,
from differences in treatment modalities [14], or
from differences in the ways patients perceive
and manage their disease.
Therefore, the aim of this study was to ana-
lyze in detail the HAT data reported by T1DM
and T2DM patients from Central and Eastern
Europe (CEE) according the patient’s perspec-
tive, which was not presented in the paper by
Khunti et al. [13]. We focused on patients’ per-
ception of hypoglycemia, the impact of hypo-
glycemia on patients’ personal and societal
functioning, and utilization of healthcare
resources.
METHODS
Study Design and Subjects
This was a multicenter, non-interventional,
two-part study based on a patient self-assess-
ment questionnaire (SAQ) comprising both a
6-month and a 4-week retrospective cross-sec-
tional evaluation (Part 1) and a 4-week
prospective observational evaluation (Part 2).
The study was conducted between 5 September
2012 and 30 December 2013 at 262 sites in CEE.
Consecutive eligible patients were enrolled in
the study during a routinely scheduled clinical
consultation with their healthcare provider.
Participants of this study came from Bulgaria,
Croatia, Czech Republic, Hungary, Poland,
Romania, Serbia and Montenegro, Slovakia, and
Slovenia.
Each country was to identify 80–150 inves-
tigators (doctors working in either primary or
secondary care). Each investigator was to recruit
and enroll five to ten consecutive patients who
met the inclusion criteria, namely, adults with
T1DM or T2DM treated with insulin for at least
12 months. Illiterate patients or patients other-
wise unable to complete a written survey were
excluded from the study. Patients who were
hospitalized at the time of study start were also
excluded.
Assessments
Part 1 of the questionnaire was used to record
baseline demographic and clinical information.
A history of hypoglycemic events was estab-
lished, with data on severe events collected for
6 months and 4 weeks, respectively, prior to
baseline and data on non-severe events col-
lected for only 4 weeks prior to baseline. Infor-
mation on each patient’s knowledge, awareness,
and fear of hypoglycemia was also collected.
Part 1 of the questionnaire was completed dur-
ing routine clinical consultations with health-
care providers.
Part 2 of the questionnaire was completed
4 weeks after baseline and evaluated the occur-
rence of both severe and non-severe hypo-
glycemic events over the 4 weeks following
entry into the baseline study. To assist recall
and maintain anonymity, patients were pro-
vided with a diary to record hypoglycemic
events. If a patient recorded more hypoglycemic
events using the patient diary than recorded in
Part 2 of the SAQ, then the data in the patient
diary were used to calculate the prevalence of
hypoglycemia in the 4 weeks after baseline as a
mean to compensate for potential underesti-
mations attributable to recall bias. Part 2 of the
questionnaire and the patient diary were
returned by post.
Parts 1 and 2 of the questionnaire were both
used to evaluate patients’ responses to hypo-
glycemic events and the effect of these events
on healthcare utilization and productivity dur-
ing the time frame of the study.
In accordance to the ADA definition, hypo-
glycemia was defined as an acute complication
of DM with a B 3.9 mmol/L (70 mg/dl) fall in
blood glucose level that exposes a patient to
potential harm [15, 16]. Non-severe
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hypoglycemia was defined as an event managed
by the patient alone; severe hypoglycemia was
defined (based on the ADA definition) as any
hypoglycemic event requiring assistance of
another person to administer carbohydrate,
glucagon, or other resuscitative actions [16].
Nocturnal hypoglycemia was defined by proto-
col as any hypoglycemic event occurring
between midnight and 0600 hours.
The awareness of hypoglycemia was catego-
rized based on answers given to the question
‘Do you have symptoms when you have a low
sugar level?’, where ‘always’ and ‘usually’
denoted normal, ‘occasionally’ denoted
impaired, and ‘never’ denoted severely impaired
awareness.
Fear of hypoglycemia was assessed by the
patients themselves on 0 to 10 semi-quantita-
tive scale, where ‘0’ denoted not afraid at all,
and ‘10’ denoted absolutely terrified.
Compliance with Ethics Guidelines
This study was conducted in accordance with
the Declaration of Helsinki (2004) and the
International Conference on Harmonization
(ICH) Guidelines for Good Clinical Practice
(1996). The study design was approved by the
country-specific regulatory authorities and eth-
ical committees. All participants of the study
provided signed informed consent.
Statistical Analysis
Baseline refers to data collected using the Part 1
SAQ, while follow-up refers to data collected
using the Part 2 SAQ and, where applicable, the
patient diary. Continuous data were summa-
rized in terms of the number of observations,
mean, standard deviation, upper quartile,
median, lower quartile, minimum, maximum,
and missing number of observations, unless
otherwise stated. Categorical data were sum-
marized in terms of the number of patients
providing data at the relevant time point (n),
frequency counts, and percentages. Incidence
rates of hypoglycemia together with the 95%
confidence intervals were calculated as the
number of events per patient year. Statistical
analysis was performed using SAS version 9.2
or later (SAS Institute, Cary, NC, USA).
RESULTS
Baseline Characteristics
In total, 10,414 patients were invited to partic-
ipate in the study. Overall, 9504 patients com-
pleted Part 1 of the SAQ (3135 with T1DM and
6369 with T2DM); 9229 patients (3040 with
T1DM and 6189 with T2DM) completed Part 2
of the SAQ, and 7647 patients (2826 with T1DM
and 4821 with T2DM) completed patient
diaries.
Demographic and Clinical Characteristics
Disposition of the patients by country was as
follows: 537 (5.6%) were from Bulgaria, 315
(3.3%) were from Croatia, 1472 (15.5%) were
from the Czech Republic, 1667 (17.5%) were
from Hungary, 2448 (25.8%) were from Poland,
1190 (12.5%) were from Romania, 1064 (11.2%)
were from Serbia and Montenegro, 500 were
from Slovakia (5.3%), and 311 were (3.3%) from
Slovenia. Patients with T1DM were younger
than those with T2DM and had a longer mean
duration of insulin use. Mean HbA1c level was
similar in both groups of patients. The last
measured HbA1c value in[ 50% of all patients
was in the range of 53–75 mmol/mol
(7.0–9.0%). Most patients were treated with
short-acting and long-acting insulins, and
about 25% of all patients took oral anti-diabetes
drugs. Most patients in the overall population
experienced hypoglycemic events. Table 1 pro-
vides detailed information on patient baseline
characteristics.
Knowledge about hypoglycemia
At baseline, most of the patients were familiar
with the definition of hypoglycemia, and most
had experienced a hypoglycemic episode. More
than 40% of patients recognized hypoglycemia
on the basis of symptoms and low blood glucose
concentration.
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Table 1 Demographic and clinical characteristics at baseline (study entry)
Demographic and clinical characteristics T1DM patients (N5 3135) T2DM patients (N5 6369)
Age (years)
Mean (SD) 42.0 (13.97)b 62.5 (9.30)b
Sex [n (%)]
Male 1511 (48.3)b 3095 (48.7)b
Female 1618 (51.7) 3265 (51.3)
Employment status [n (%)]
Student 234 (7.5) 3 (\0.1)
Full-time employment 1539 (49.5) 1140 (18.1)
Part-time employment 244 (7.8) 327 (5.2)
Unemployed 272 (8.7) 296 (4.7)
Pensioned 689 (22.1) 4427 (70.3)
Other 133 (4.3) 107 (1.7)
Duration of diabetes (years)
n 3130 6331
Mean (SD) 16.8 (11.17)b 13.6 (7.87)b
Duration of insulin treatment (years)
n 3132 6351
Mean (SD) 16.3 (11.17)b 7.1 (5.78)b
Self-reported last HbA1c (mmol/mol) levels
n 2879 5438
Mean (SD) 61.0 (15.68)b 60.9 (15.02)b
Self-reported last HbA1c (%) levelsa
Mean (SD) 7.7 (3.6) 7.7 (3.5)
Patients with self-reported last HbA1c (%) levels [n (%)]
n 2879 5438
\ 7.0%, 905 (31.4) 1549 (28.5)
C 7.0% and B 9.0% 1513 (52.6) 3147 (57.9)
[ 9.0% 461 (16.0) 742 (13.6)
Treatment of diabetes [n (%)]
Short-acting insulin 2718 (86.9) 3451 (54.6)
Long-acting insulin 2525 (80.7) 3895 (61.6)
Mixed insulin 166 (5.3) 2381 (37.6)
Insulin pump 416 (13.3) 53 (0.8)
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In total, a minority of patients who used
blood glucose measurement to determine if
they had hypoglycemia provided values incon-
sistent with the standard definition of a hypo-
glycemic event. These details are given in
Table 2.
Incidence, Awareness and Fear
of Hypoglycemia
Incidence of Hypoglycemia
During the 4 weeks preceding baseline, most of
patients reported at least one hypoglycemic
event. During the 4 weeks after baseline, the
percentages of patients who reported hypo-
glycemic events were similar to those in the
4 weeks prior to baseline (Table 3).
The incidence of patient-reported nocturnal
hypoglycemic events was much higher in the
T1DM patient population than in the T2DM
patient population (Table 3).
Awareness of Hypoglycemia
Hypoglycemia awareness at baseline was similar
in T1DM and T2DM patients. Most patients
reported normal awareness (85.4% of T1DM
and 83.6% of T2DM patients). Approximately
13% of all patients had impaired hypoglycemia
awareness (13.3% of T1DM and 13.4% of T2DM
patients). A minority had severely impaired
hypoglycemia awareness (1.3% of T1DM and
3.1% of T2DM patients).
Fear of Hypoglycemia
At baseline, responses from T1DM patients
indicated a greater fear of hypoglycemia than
did those those of T2DM patients (Fig. 1).
Patient Actions due to Hypoglycemia
A hypoglycemic event resulted in most patients
increasing glucose self-monitoring, consulting a
doctor or a nurse, and/or reducing the insulin
dose (Table 4).
Table 1 continued
Demographic and clinical characteristics T1DM patients (N5 3135) T2DM patients (N5 6369)
Oral anti-diabetes treatments 84 (2.7) 2124 (33.6)
Injectable anti-diabetes treatments (excluding insulin) 3 (\0.1) 51 (0.8)
Use of continuous glucose monitoring device [n (%)]
Yes 536 (17.4) 715 (11.5)
No 2486 (80.9) 5338 (85.9)
Not sure 52 (1.7) 160 (2.6)
Self-measurement of blood glucose levels [n (%)]
Yes 3119 (99.6) 6303 (99.1)
No 12 (0.4) 58 (0.9)
Self-reported hypoglycemia [n (%)]
Yes 3069 (98.3) 5357 (84.6)
No 44 (1.4) 829 (13.1)
Not sure 8 (0.3) 143 (2.3)
HbA1c Glycated hemoglobin; SD standard deviation, T1DM type 1 diabetes, T2DM type 2 diabetes
a Calculated
b Reported previously by Khunti et al. [13]
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Impact of Hypoglycemia on Healthcare
Services—Direct Costs
The occurrence of hypoglycemia in the retro-
spective and prospective parts of the study led
patients with T1DM to make additional tele-
phone contact with a doctor or a nurse (15.5
and 9.2%, respectively) or to attend additional
clinical appointments (7.1 and 3.0%, respec-
tively). During the 6 months prior to baseline,
97 (3.5%) patients with T1DM had a hypo-
glycemic event requiring hospitalization, and
during the 4 weeks after baseline, hypoglycemia
occurred in 31 (1.2%) patients.
In the retrospective period, 652 (16.6%)
patients with T2DM consulted medical profes-
sionals by telephone as a result a hypoglycemic
event compared to 409 (14.2%) in the prospec-
tive period. Additional clinical appointments
were made by 302 (7.7%) patients with T2DM in
the 6 months preceding baseline and by 147
(5.1%) patients during the 4 weeks after base-
line. In the 6 months preceding baseline, 141
(3.4%) patients with T2DM required hospital-
ization due to hypoglycemia compared to 66
(2.1%) during the 4 weeks after baseline.
Table 2 Patient knowledge of hypoglycemia (baseline)
Patient knowledge of hypoglycemia at baseline T1DM patients
(N5 3135)
T2DM patients
(N5 6369)
Knowledge of the deﬁnition of hypoglycemia [n/N total (%)] 3061/3121 (98.1) 5835/6330 (92.2)
Experienced hypoglycemia [n/N total (%)] 3069/3121 (98.3) 5357/6329 (84.6)
Self-recognition of hypoglycemia based on [n/N total (%)]:
Symptoms only 874/3041 (28.7) 1786/5245 (34.1)
Low blood glucose only 117/3041 (3.8) 325/5245 (6.7)
Either symptoms or low blood glucose 618/3041 (20.3) 762/5245 (14.5)
Both symptoms and low blood glucose 1432/3041 (47.1) 2345/5245 (44.7)
Blood glucose measurement to determine if they have hypoglycemia but
provided values inconsistent with standard deﬁnitions (B 3.9 mmol/L;
70 mg/dl) [n/N total (%)]
372/2875 (12.9) 932/4711 (19.8)
Blood glucose level below which patients considered was a hypoglycemic event
(mmol/L) in patients providing values consistent with standard deﬁnition,
mean (SD)
3.16 (0.550) 3.22 (0.534)
Blood glucose level below which patients considered was a hypoglycemic event
(mg/dl) in patients providing values consistent with standard deﬁnition,
mean (SD)a
56.9 (9.91) 58.0 (9.62)
Blood glucose level below which patients considered was a hypoglycemic event
(mmol/L) in patients providing values inconsistent with standard deﬁnition,
mean (SD)
4.34 (0.608) 4.47 (0.625)
Blood glucose level below which patients considered was a hypoglycemic event
(mg/dl) in patients providing values inconsistent with standard deﬁnition,
mean (SD)a
78.2 (10.95) 80.5 (11.26)
a Calculated
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Table 3 Incidence of hypoglycemic events in the 4 weeks before and 4 weeks after baseline (by diabetes type)
Incidence of
hypoglycemic events
T1DM patients: 4
weeks before
baseline (N5 3052)
T1DM patients: 4
weeks after baseline
(N5 3052)
T2DM patients: 4
weeks before
baseline (N5 6218)
T2DM patients 4
weeks after baseline
(N5 6218)
Number of patients with
any hypoglycemic event
[n (%)]
2560 (84.3) 2583 (85.0)a 3509 (57.0) 3312 (53.8)a
Incidence rate ratio
(4 weeks after/4 weeks
before)
1.55 1.19
95% CI for incidence
ratio
1.45, 1.65 1.11, 1.27
Number of patients with a
severe hypoglycemic
event [n (%)]
365 (12.2) 395 (13.0) 408 (6.7) 469 (7.6)
Incidence rate ratio
(4 weeks after/4 weeks
before)
1.30 1.35
95% CI for incidence
ratio
1.07, 1.58 1.07, 1.70
Number of patients with a
nocturnal hypoglycemic
event
[n (%)]
1305 (43.8) 1142 (38.8) 1358 (22.7) 1024 (17.3)
Incidence rate ratio
(4 weeks after/4 weeks
before)
0.77 0.70
95% CI for incidence
ratio
0.69, 0.85 0.64, 0.77
Number of patients with a
non-severe
hypoglycemic event
[n (%)]
2490 (82.9) 2550 (84.5) 3420 (57.0) 3238 (53.7)
Incidence rate ratio
(4 weeks after/4 weeks
before)
1.56 1.16
95% CI for incidence
ratio
1.46, 1.67 1.09, 1.24
CI Conﬁdence interval
a Reported previously by Khunti et al. [13]
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Impact of Hypoglycemia on Work
and Study Attendance—Indirect Costs
Most patients with T1DM enrolled in the study
were studying or working (2017 before baseline,
1957 in the 4 weeks after baseline). In the
prospective period, 40 (2.5%) of these patients
had taken some form of leave from work or
studies (mean duration 2.3 ± 2.15 days), 68
(4.3%) had arrived late to their study or working
Fig. 1 Fear of hypoglycemia by diabetes type at baseline. T1DM Type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
Table 4 Patient actions resulting from a hypoglycemic event 6 months before and 4 weeks after baseline by diabetes type
Patient actions T1DM patients: 6
months before
baseline (N5 2797)
T2DM patients: 6
months before
baseline (N5 4129)
T1DM patients: 4
weeks after baseline
(N5 2515)
T2DM patients: 4
weeks after baseline
(N5 3140)
Consulted their
doctor/nurse [n (%)]
1938 (70.7) 2960 (75.3) 1266 (53.0) 1822 (63.2)
Required any form of
medical assistance
[n (%)]
1954 (71.3) 3005 (76.5) 1280 (53.6) 1843 (63.9)
Increased carbohydrate
intake (sugar or
snacks)
[n (%)]
1352 (50.5) 2080 (53.0) 1255 (52.3) 1544 (52.0)
Avoided physical
exercise [n (%)]
585 (22.5) 910 (24.0) 499 (21.2) 694 (23.9)
Reduced insulin dose
[n (%)]
1702 (63.5) 1720 (44.5) 1248 (51.7) 1205 (40.6)
Skipped insulin
injections [n (%)]
354 (13.6) 423 (11.2) 199 (8.5) 202 (6.9)
Increased blood glucose
self-monitoring
[n (%)]
2059 (76.7) 2747 (71.0) 1831 (75.7) 2152 (71.9)
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place, and 64 (4.0%) had to leave early due to
hypoglycemic events. In the retrospective per-
iod prior to baseline, 225 (11.4%) had taken
leave (mean duration 4.7 ± 8.09 days), 316
(16.0%) had arrived late, and 309 (15.6%) had
left work/studies early.
Among the 1431 patients with T2DM who
were studying or employed in the 4-week
prospective period, 19 (2.5%) had taken leave
from work or studies (mean duration
2.8 ± 4.97 days), 20 (2.7%) had arrived late to
their place of study or work, and 37 (4.9%) had
to leave early due to hypoglycemic events. In
the retrospective period prior to baseline, 74
(5.1%) had taken leave (mean duration
3.3 ± 3.09 days), 91 (6.4%) had arrived late, and
120 (8.4%) had left work/studies early.
DISCUSSION
The manner in which patients perceive hypo-
glycemia, how they handle hypoglycemic events
and to what extent these complications affect
patient actions and healthcare utilization were
part of the HAT survey. Although these data were
not presented for the total HAT population in a
previous publication reporting the global HAT
results [13], we consider such information to be
important with respect to providing further
insights into hypoglycemia prevention. There-
fore, we undertook a detailed examination of
these data for the CEE subpopulation.
We observed similar percentages of patients
who reported hypoglycemic events in the ret-
rospective and prospective phase of our study.
Our interpretation is that once patients started
the study, they became more compliant and
thus their diabetes was better controlled, possi-
bly including a lower actual rate of
hypoglycemia.
Impaired hypoglycemia awareness is one of
the strongest risk factors for severe hypo-
glycemia [17] and has been reported to increase
the risk of severe hypoglycemia in T1DM
patients by up to sixfold [18]. Data on the pro-
portion of T1DM and T2DM patients unaware
of hypoglycemia varies significantly among
studies [11, 18–25]. In our study, most T1DM
patients (85.4%) reported a normal level of
hypoglycemia awareness, and only 13.3% of
T1DM patients reported an impaired awareness.
The difference in the percentage of patients
reporting impaired hypoglycemia awareness in
this study as compared to previous research may
be explained by the different ways the patient
responses were classified. Most studies con-
ducted to date have used a rigid classification
proposed by Pedersen-Bjergaard et al. [26]. In
our study, patients who answered the question
‘Do you have symptoms when you have a low
sugar level?’ with ‘always’ or ‘usually’ were
classified as having a normal level of hypo-
glycemia awareness, those who answered ‘oc-
casionally’ were classified as impaired, and
those who answered ‘never’ were classed as
severely impaired. However, this classification
of hypoglycemia awareness relies on patients’
subjective assessments and as such was not
validated. Therefore, this methodology needs to
be considered as one of the study limitations.
In our study, the fear of hypoglycemia was
slightly higher in patients with T1DM than in
patients with T2DM. However, most T1DM and
T2DM patients scored their fear level as 5 in the
10-point scale (where 10 was ‘absolutely terri-
fied’). Hypoglycemia fear influences glycemic
variability, dietary patterns, and physical activ-
ity in patients with T1DM, as shown by Martyn-
Nemeth et al. whose patients increased calorie
intake and reduced physical activity due to their
fear of hypoglycemia [27]. Other studies have
found that fear of hypoglycemia is associated
with diabetes-related QoL and psychological
well-being [28, 29]. The fear of hypoglycemia is
also a major reason for discontinuation of dia-
betes medications by T2DM patients [29, 30].
The occurrence of a hypoglycemic event
resulted in most of the patients in our study
increasing glucose self-monitoring and/or con-
sulting a doctor or a nurse. Patients with T1DM
were slightly more likely to increase the fre-
quency of glucose self-monitoring compared to
T2DM patients, but they were also more aware
of hypoglycemic events. However, more than
half of the T2DM patients decreased the insulin
dose and some skipped insulin injections,
which can in turn lead to poor glycemic control
and increased risk of related health conse-
quences, such as CV disorders.
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The results of our study reflect patient reac-
tions reported in previous studies. Fulcher et al.
followed patient responses to nocturnal and
daytime non-severe hypoglycemic events and
reported that these patients decreased insulin
dosage, contacted a healthcare professional,
and performed additional blood testing in the
week following the event [31]. Brod et al. also
reported similar patient reactions to non-severe
nocturnal hypoglycemia, namely, extra blood
glucose level tests and reduced insulin dosage
[32].
In our study we found that hypoglycemia
resulted in an increased use of healthcare ser-
vices and a decrease in work/study productiv-
ity—responses supported by previous research
[31–33]. In the analysis by Fidler et al., hypo-
glycemia was associated with a reduction in
QoL, increased fear and anxiety, reduced pro-
ductivity, and increased healthcare costs [34].
Widz et al. estimated the average monthly
direct cost of a hypoglycemic event to be
approximately 700 EUR for severe events and 40
EUR for non-severe events [35]. In addition,
Goldstein et al. found that severe hypoglycemic
events increased the use of healthcare resources
and healthcare costs during the month after the
event as compared to the month before, with
hospital admissions increasing by almost by
100% for T1DM patients and by 127% for T2DM
patients, and the mean duration of hospital-
ization being longer [36]. The number of out-
patient visits increased by 37% (T1DM) and
47% (T2DM). As a result, total monthly
healthcare costs increased by 46% in T1DM
patients and by 87% in T2DM patients [36].
An earlier analysis from seven European
countries revealed that approximately 10% of
both daytime and nocturnal non-severe hypo-
glycemic events led to mean work-time loss of
about 1–3 h [33]. Annual costs of severe hypo-
glycemic events in nine European countries
were estimated to be approximately 380,000
EUR in Macedonia ranging up to 58,430,000
EUR in Spain. When expressed as cost per drug-
treated patient, the costs ranged from 5.5 EUR
in Bulgaria to 17.7 EUR in Spain. The differences
were attributable to the costs of a single event
treatment and general differences in rates [37].
We also report how hypoglycemia affected
patient absenteeism: patients arrived late at
work/study, had to leave early, and 2.5% of
them needed to take sick leave. Hypoglycemic
events also led to an increase in healthcare ser-
vices usage. Therefore, minimizing hypo-
glycemia risk while maintaining good glycemic
control may reduce the overall costs of diabetes
by diminishing direct costs related to the use of
healthcare services and indirect costs by
increasing work productivity.
The limitation of the HAT was its observa-
tional design with a longer retrospective time
horizon and much shorter duration of the
prospective phase. Therefore, the comparisons
between the results from the retrospective and
prospective phases should be interpreted with
caution, mainly because of possible recall bias.
For example, healthcare utilization or work or
study attendance seem to be much lower during
the retrospective phase than in the prospective
phase, but this difference may be a consequence
of underreporting, caused by a recall bias.
Another limitation relates to the eligibility cri-
terion that only patients attending routinely
scheduled clinical consultations could be
enrolled in the study. Illiterate patients or
patients otherwise unable to complete a written
survey, i.e. patients at the lowest cultural/socio-
economic level were excluded from the study,
possibly introducing a population bias. How-
ever, the study included a large patient popu-
lation and allowed us to determine the real-life
incidence of hypoglycemia as reported by
patients. In addition, the HAT study enabled
assessment of the impact of hypoglycemia on
patients’ reactions, use of healthcare service,
and work/study productivity. Another strong
feature of the HAT study was that during the
prospective period, patient diaries were used in
addition to Part 2 of the SAQ to reduce recall
bias. While the use of patient-reported data
from the diaries in addition to Part 2 of the SAQ
may have increased the reliability of the data
pertaining to the prevalence of hypoglycemia, it
has the potential to overestimate hypoglycemia
rates.
It should be also highlighted that this anal-
ysis is entirely based on patient self-reported
data. Patient-reported outcomes provide a clear
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picture of the patient’s perspective and percep-
tion. On the other hand, they are inevitably
subjective and susceptible to imprecision and
variation. Nevertheless, such self-assessments
are inherent elements of a patient-centered
healthcare system [38], which is particularly
suited to diabetes where disease self-manage-
ment is crucial for proper treatment.
CONCLUSIONS
In conclusion, our study shows that hypo-
glycemia impacts patients’ personal and social
functioning and leads to additional healthcare
usage and loss of productivity. Based on these
results, we suggest that there is a room for
improving education relating to the way hypo-
glycemia is recognized by patients. We believe
that the results of our study can be used to
identify cost-effective solutions for improving
blood glucose control and the QoL of patients
with DM.
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